Clinical Trial Update: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma [NA]

View source ↗

Summary

This clinical trial update discusses the use of DSC-MRI derived rCBV to measure early response to bevacizumab in patients with recurrent glioblastoma, with the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Gliosarcoma, Recurrent Glioblastoma | NA | Status: ACTIVE_NOT_RECRUITING